Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma
Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Pal, Sumanta K. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
3 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise - Feng, Jing ELSEVIER, 2018, official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:78 ; year:2020 ; number:6 ; pages:783-785 ; extent:3 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.eururo.2020.08.007 |
|---|
| Katalog-ID: |
ELV052192067 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV052192067 | ||
| 003 | DE-627 | ||
| 005 | 20230626032943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eururo.2020.08.007 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001407.pica |
| 035 | |a (DE-627)ELV052192067 | ||
| 035 | |a (ELSEVIER)S0302-2838(20)30624-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 500 |q VZ |
| 084 | |a 33.25 |2 bkl | ||
| 084 | |a 31.00 |2 bkl | ||
| 100 | 1 | |a Pal, Sumanta K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma |
| 264 | 1 | |c 2020transfer abstract | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. | ||
| 520 | |a Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. | ||
| 650 | 7 | |a TIVO-3 |2 Elsevier | |
| 650 | 7 | |a VEGF inhibitor |2 Elsevier | |
| 650 | 7 | |a Sorafenib |2 Elsevier | |
| 650 | 7 | |a Tivozanib |2 Elsevier | |
| 650 | 7 | |a Overall survival |2 Elsevier | |
| 700 | 1 | |a Escudier, Bernard J. |4 oth | |
| 700 | 1 | |a Atkins, Michael B. |4 oth | |
| 700 | 1 | |a Hutson, Thomas E. |4 oth | |
| 700 | 1 | |a Porta, Camillo |4 oth | |
| 700 | 1 | |a Verzoni, Elena |4 oth | |
| 700 | 1 | |a Needle, Michael N. |4 oth | |
| 700 | 1 | |a Powers, Daniel |4 oth | |
| 700 | 1 | |a McDermott, David F. |4 oth | |
| 700 | 1 | |a Rini, Brian I. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Feng, Jing ELSEVIER |t Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |d 2018 |d official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology |g Amsterdam [u.a.] |w (DE-627)ELV000464341 |
| 773 | 1 | 8 | |g volume:78 |g year:2020 |g number:6 |g pages:783-785 |g extent:3 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.eururo.2020.08.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 33.25 |j Thermodynamik |j statistische Physik |q VZ |
| 936 | b | k | |a 31.00 |j Mathematik: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 78 |j 2020 |e 6 |h 783-785 |g 3 | ||
| author_variant |
s k p sk skp |
|---|---|
| matchkey_str |
palsumantakescudierbernardjatkinsmichael:2020----:iaoealuvvleutfoahs3tdtcmaeioaitsrfnbshrofutlnteaynuj |
| hierarchy_sort_str |
2020transfer abstract |
| bklnumber |
33.25 31.00 |
| publishDate |
2020 |
| allfields |
10.1016/j.eururo.2020.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001407.pica (DE-627)ELV052192067 (ELSEVIER)S0302-2838(20)30624-2 DE-627 ger DE-627 rakwb eng 500 VZ 33.25 bkl 31.00 bkl Pal, Sumanta K. verfasserin aut Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma 2020transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival Elsevier Escudier, Bernard J. oth Atkins, Michael B. oth Hutson, Thomas E. oth Porta, Camillo oth Verzoni, Elena oth Needle, Michael N. oth Powers, Daniel oth McDermott, David F. oth Rini, Brian I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:78 year:2020 number:6 pages:783-785 extent:3 https://doi.org/10.1016/j.eururo.2020.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 78 2020 6 783-785 3 |
| spelling |
10.1016/j.eururo.2020.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001407.pica (DE-627)ELV052192067 (ELSEVIER)S0302-2838(20)30624-2 DE-627 ger DE-627 rakwb eng 500 VZ 33.25 bkl 31.00 bkl Pal, Sumanta K. verfasserin aut Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma 2020transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival Elsevier Escudier, Bernard J. oth Atkins, Michael B. oth Hutson, Thomas E. oth Porta, Camillo oth Verzoni, Elena oth Needle, Michael N. oth Powers, Daniel oth McDermott, David F. oth Rini, Brian I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:78 year:2020 number:6 pages:783-785 extent:3 https://doi.org/10.1016/j.eururo.2020.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 78 2020 6 783-785 3 |
| allfields_unstemmed |
10.1016/j.eururo.2020.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001407.pica (DE-627)ELV052192067 (ELSEVIER)S0302-2838(20)30624-2 DE-627 ger DE-627 rakwb eng 500 VZ 33.25 bkl 31.00 bkl Pal, Sumanta K. verfasserin aut Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma 2020transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival Elsevier Escudier, Bernard J. oth Atkins, Michael B. oth Hutson, Thomas E. oth Porta, Camillo oth Verzoni, Elena oth Needle, Michael N. oth Powers, Daniel oth McDermott, David F. oth Rini, Brian I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:78 year:2020 number:6 pages:783-785 extent:3 https://doi.org/10.1016/j.eururo.2020.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 78 2020 6 783-785 3 |
| allfieldsGer |
10.1016/j.eururo.2020.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001407.pica (DE-627)ELV052192067 (ELSEVIER)S0302-2838(20)30624-2 DE-627 ger DE-627 rakwb eng 500 VZ 33.25 bkl 31.00 bkl Pal, Sumanta K. verfasserin aut Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma 2020transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival Elsevier Escudier, Bernard J. oth Atkins, Michael B. oth Hutson, Thomas E. oth Porta, Camillo oth Verzoni, Elena oth Needle, Michael N. oth Powers, Daniel oth McDermott, David F. oth Rini, Brian I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:78 year:2020 number:6 pages:783-785 extent:3 https://doi.org/10.1016/j.eururo.2020.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 78 2020 6 783-785 3 |
| allfieldsSound |
10.1016/j.eururo.2020.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001407.pica (DE-627)ELV052192067 (ELSEVIER)S0302-2838(20)30624-2 DE-627 ger DE-627 rakwb eng 500 VZ 33.25 bkl 31.00 bkl Pal, Sumanta K. verfasserin aut Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma 2020transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival Elsevier Escudier, Bernard J. oth Atkins, Michael B. oth Hutson, Thomas E. oth Porta, Camillo oth Verzoni, Elena oth Needle, Michael N. oth Powers, Daniel oth McDermott, David F. oth Rini, Brian I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:78 year:2020 number:6 pages:783-785 extent:3 https://doi.org/10.1016/j.eururo.2020.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 78 2020 6 783-785 3 |
| language |
English |
| source |
Enthalten in Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise Amsterdam [u.a.] volume:78 year:2020 number:6 pages:783-785 extent:3 |
| sourceStr |
Enthalten in Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise Amsterdam [u.a.] volume:78 year:2020 number:6 pages:783-785 extent:3 |
| format_phy_str_mv |
Article |
| bklname |
Thermodynamik statistische Physik Mathematik: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
TIVO-3 VEGF inhibitor Sorafenib Tivozanib Overall survival |
| dewey-raw |
500 |
| isfreeaccess_bool |
false |
| container_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| authorswithroles_txt_mv |
Pal, Sumanta K. @@aut@@ Escudier, Bernard J. @@oth@@ Atkins, Michael B. @@oth@@ Hutson, Thomas E. @@oth@@ Porta, Camillo @@oth@@ Verzoni, Elena @@oth@@ Needle, Michael N. @@oth@@ Powers, Daniel @@oth@@ McDermott, David F. @@oth@@ Rini, Brian I. @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000464341 |
| dewey-sort |
3500 |
| id |
ELV052192067 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052192067</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626032943.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eururo.2020.08.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001407.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052192067</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0302-2838(20)30624-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.25</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pal, Sumanta K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TIVO-3</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VEGF inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sorafenib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tivozanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Overall survival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Escudier, Bernard J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Atkins, Michael B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hutson, Thomas E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Porta, Camillo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verzoni, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Needle, Michael N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Powers, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McDermott, David F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rini, Brian I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Feng, Jing ELSEVIER</subfield><subfield code="t">Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise</subfield><subfield code="d">2018</subfield><subfield code="d">official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000464341</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:78</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:783-785</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.eururo.2020.08.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.25</subfield><subfield code="j">Thermodynamik</subfield><subfield code="j">statistische Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.00</subfield><subfield code="j">Mathematik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">78</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield><subfield code="h">783-785</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| author |
Pal, Sumanta K. |
| spellingShingle |
Pal, Sumanta K. ddc 500 bkl 33.25 bkl 31.00 Elsevier TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma |
| authorStr |
Pal, Sumanta K. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000464341 |
| format |
electronic Article |
| dewey-ones |
500 - Natural sciences & mathematics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
500 VZ 33.25 bkl 31.00 bkl Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival Elsevier |
| topic |
ddc 500 bkl 33.25 bkl 31.00 Elsevier TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival |
| topic_unstemmed |
ddc 500 bkl 33.25 bkl 31.00 Elsevier TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival |
| topic_browse |
ddc 500 bkl 33.25 bkl 31.00 Elsevier TIVO-3 Elsevier VEGF inhibitor Elsevier Sorafenib Elsevier Tivozanib Elsevier Overall survival |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b j e bj bje m b a mb mba t e h te teh c p cp e v ev m n n mn mnn d p dp d f m df dfm b i r bi bir |
| hierarchy_parent_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| hierarchy_parent_id |
ELV000464341 |
| dewey-tens |
500 - Science |
| hierarchy_top_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000464341 |
| title |
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma |
| ctrlnum |
(DE-627)ELV052192067 (ELSEVIER)S0302-2838(20)30624-2 |
| title_full |
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma |
| author_sort |
Pal, Sumanta K. |
| journal |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| journalStr |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
783 |
| author_browse |
Pal, Sumanta K. |
| container_volume |
78 |
| physical |
3 |
| class |
500 VZ 33.25 bkl 31.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Pal, Sumanta K. |
| doi_str_mv |
10.1016/j.eururo.2020.08.007 |
| dewey-full |
500 |
| title_sort |
final overall survival results from a phase 3 study to compare tivozanib to sorafenib as third- or fourth-line therapy in subjects with metastatic renal cell carcinoma |
| title_auth |
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma |
| abstract |
Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. |
| abstractGer |
Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. |
| abstract_unstemmed |
Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| container_issue |
6 |
| title_short |
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma |
| url |
https://doi.org/10.1016/j.eururo.2020.08.007 |
| remote_bool |
true |
| author2 |
Escudier, Bernard J. Atkins, Michael B. Hutson, Thomas E. Porta, Camillo Verzoni, Elena Needle, Michael N. Powers, Daniel McDermott, David F. Rini, Brian I. |
| author2Str |
Escudier, Bernard J. Atkins, Michael B. Hutson, Thomas E. Porta, Camillo Verzoni, Elena Needle, Michael N. Powers, Daniel McDermott, David F. Rini, Brian I. |
| ppnlink |
ELV000464341 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.eururo.2020.08.007 |
| up_date |
2024-07-06T22:21:15.607Z |
| _version_ |
1803869985815134208 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV052192067</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626032943.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eururo.2020.08.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001407.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV052192067</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0302-2838(20)30624-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.25</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pal, Sumanta K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56–0.94; p =0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75–1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TIVO-3</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VEGF inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sorafenib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tivozanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Overall survival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Escudier, Bernard J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Atkins, Michael B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hutson, Thomas E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Porta, Camillo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verzoni, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Needle, Michael N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Powers, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McDermott, David F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rini, Brian I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Feng, Jing ELSEVIER</subfield><subfield code="t">Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise</subfield><subfield code="d">2018</subfield><subfield code="d">official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000464341</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:78</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:783-785</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.eururo.2020.08.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.25</subfield><subfield code="j">Thermodynamik</subfield><subfield code="j">statistische Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.00</subfield><subfield code="j">Mathematik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">78</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield><subfield code="h">783-785</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| score |
7.399666 |